Literature DB >> 26930359

Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures.

Kathrin Töllner1, Friederike Twele1, Wolfgang Löscher2.   

Abstract

Resistance to antiepileptic drugs (AEDs) is a major problem in epilepsy therapy, so that development of more effective AEDs is an unmet clinical need. Several rat and mouse models of epilepsy with spontaneous difficult-to-treat seizures exist, but because testing of antiseizure drug efficacy is extremely laborious in such models, they are only rarely used in the development of novel AEDs. Recently, the use of acute seizure tests in epileptic rats or mice has been proposed as a novel strategy for evaluating novel AEDs for increased antiseizure efficacy. In the present study, we compared the effects of five AEDs (valproate, phenobarbital, diazepam, lamotrigine, levetiracetam) on the pentylenetetrazole (PTZ) seizure threshold in mice that were made epileptic by pilocarpine. Experiments were started 6 weeks after a pilocarpine-induced status epilepticus. At this time, control seizure threshold was significantly lower in epileptic than in nonepileptic animals. Unexpectedly, only one AED (valproate) was less effective to increase seizure threshold in epileptic vs. nonepileptic mice, and this difference was restricted to doses of 200 and 300 mg/kg, whereas the difference disappeared at 400mg/kg. All other AEDs exerted similar seizure threshold increases in epileptic and nonepileptic mice. Thus, induction of acute seizures with PTZ in mice pretreated with pilocarpine does not provide an effective and valuable surrogate method to screen drugs for antiseizure efficacy in a model of difficult-to-treat chronic epilepsy as previously suggested from experiments with this approach in rats.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal models; Antiepileptic drugs; Drug resistance; Epilepsy; Levetiracetam; Phenobarbital; Valproate

Mesh:

Substances:

Year:  2016        PMID: 26930359     DOI: 10.1016/j.yebeh.2016.01.032

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  6 in total

1.  Semaphorin 4D promotes inhibitory synapse formation and suppresses seizures in vivo.

Authors:  Daniel W M Acker; Irene Wong; Mihwa Kang; Suzanne Paradis
Journal:  Epilepsia       Date:  2018-05-25       Impact factor: 5.864

Review 2.  Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.

Authors:  Wolfgang Löscher
Journal:  Neurochem Res       Date:  2017-03-13       Impact factor: 3.996

3.  Small loci of astroglial glutamine synthetase deficiency in the postnatal brain cause epileptic seizures and impaired functional connectivity.

Authors:  Maxwell G Farina; Mani Ratnesh S Sandhu; Maxime Parent; Basavaraju G Sanganahalli; Matthew Derbin; Roni Dhaher; Helen Wang; Hitten P Zaveri; Yun Zhou; Niels C Danbolt; Fahmeed Hyder; Tore Eid
Journal:  Epilepsia       Date:  2021-09-18       Impact factor: 5.864

Review 4.  The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?

Authors:  Wolfgang Löscher
Journal:  Neurochem Res       Date:  2016-08-08       Impact factor: 3.996

5.  Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy.

Authors:  Carmen De Caro; Antonio Leo; Valentina Nesci; Carla Ghelardini; Lorenzo di Cesare Mannelli; Pasquale Striano; Carmen Avagliano; Antonio Calignano; Paolo Mainardi; Andrew Constanti; Rita Citraro; Giovambattista De Sarro; Emilio Russo
Journal:  Sci Rep       Date:  2019-09-27       Impact factor: 4.379

6.  Reversing frontal disinhibition rescues behavioural deficits in models of CACNA1A-associated neurodevelopment disorders.

Authors:  Alexis Lupien-Meilleur; Xiao Jiang; Mathieu Lachance; Vincent Taschereau-Dumouchel; Louise Gagnon; Catherine Vanasse; Jean-Claude Lacaille; Elsa Rossignol
Journal:  Mol Psychiatry       Date:  2021-06-14       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.